Irinotecan

Topoisomerase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Irinotecan is an ofp drug in the Topoisomerase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1996. Its mechanism of action is classified as Topoisomerase Inhibitors. DrugCentral lists 16 molecular targets, including ache, ACHE and CHRM4. Recorded indications include Adenocarcinoma of pancreas, Metastasis from malignant tumor of colon and Secondary malignant neoplasm of pancreas.

• Approval status: ofp (first approved 1996 by the FDA).
• Drug class: Topoisomerase Inhibitor.
• Mechanism of action: Topoisomerase Inhibitors.
• Molecular targets: ache, ACHE, CHRM4 and ADRA2C (16 listed in DrugCentral).
• Indications: Adenocarcinoma of pancreas, Metastasis from malignant tumor of colon and Secondary malignant neoplasm of pancreas.
• ATC code: L01CE02 (Topoisomerase 1 (TOP1) inhibitors).
• Molecular formula: C33H38N4O6; molecular weight 586.69 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Adenocarcinoma of pancreas
• Metastasis from malignant tumor of colon
• Secondary malignant neoplasm of pancreas

Off-label uses (5)

• Astrocytoma, anaplastic
• Ewing's sarcoma
• Glioblastoma multiforme of brain
• Non-small cell lung cancer
• Small cell carcinoma of lung

Contraindications (19)

• Acute pancreatitis
• Anemia
• Bone marrow depression
• Breastfeeding (mother)
• Chronic lung disease
• Dehydration
• Diarrhea
• Disease of liver
• Hyperbilirubinemia
• Interstitial pneumonia
• Intestinal obstruction
• Kidney disease
• Neutropenic disorder
• Pregnancy, function
• Renal dialysis
• Sepsis syndrome
• Thrombocytopenic disorder
• Thromboembolic disorder
• UGT1A1*28 polymorphism

Mechanism & targets

• Mechanism of action (MoA): Topoisomerase Inhibitors
• Established pharmacologic class: Topoisomerase Inhibitor

Molecular targets (16)

Target	Gene	Action	Activity
Acetylcholinesterase	ache	unknown	Ki 7.58
Acetylcholinesterase	ACHE	unknown	Ki 7.30
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 6.66
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 6.34
Multidrug and toxin extrusion protein 1	SLC47A1	unknown	IC50 5.68
Solute carrier family 22 member 2	SLC22A2	unknown	IC50 5.57
Interstitial collagenase	MMP1	unknown	IC50 5.22
Multidrug and toxin extrusion protein 2	SLC47A2	unknown	IC50 5.10
Solute carrier family 22 member 1	SLC22A1	unknown	IC50 4.68
Solute carrier family 22 member 3	SLC22A3	unknown	IC50 4.13
DNA topoisomerase 1	TOP1	inhibitor	—
Canalicular multispecific organic anion transporter 1	ABCC2	unknown	—
Multidrug resistance-associated protein 1	ABCC1	unknown	—
ATP-binding cassette sub-family G member 2	ABCG2	unknown	—
Multidrug resistance-associated protein 4	ABCC4	unknown	—
Multidrug resistance protein 1	ABCB1	unknown	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2020-03-25	PMDA	—	Nihon Servier Co., Ltd
1996-06-14	FDA	—	PFIZER INC

ATC classification

ATC code	Therapeutic hierarchy
L01CE02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS › Topoisomerase 1 (TOP1) inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: UGT1A1 · Actionable PGx
• FDA label: UGT1A1 · Testing Recommended
• HCSC label: UGT1A1 · Testing Recommended
• PMDA label: UGT1A1 · Testing Recommended
• Swissmedic label: UGT1A1 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Disease progression	3483.8
Neutropenia	3306.8
Diarrhoea	3259.2
Neuropathy peripheral	1817.5
Myelosuppression	1444.4
Febrile neutropenia	1285.7
Palmar-plantar erythrodysaesthesia syndrome	1104.6
Malignant neoplasm progression	1100.6
Skin toxicity	973.9
Dermatitis acneiform	950.1
Thrombocytopenia	937.7
Neoplasm progression	878.3

Chemical structure

• Molecular formula: C₃₃H₃₈N₄O₆
• Molecular weight: 586.69 g/mol
• CAS number: 97682-44-5
• InChIKey: UWKQSNNFCGGAFS-XIFFEERXSA-N
• PubChem CID: 60838

CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Irinotecan used for?

DrugCentral lists the following indications for Irinotecan: Adenocarcinoma of pancreas, Metastasis from malignant tumor of colon and Secondary malignant neoplasm of pancreas.

How does Irinotecan work?

Irinotecan is classified as Topoisomerase Inhibitors; its molecular targets in DrugCentral include ache, ACHE, CHRM4 and ADRA2C.

When was Irinotecan first approved?

Irinotecan was first approved by the FDA in 1996.

What drug class does Irinotecan belong to?

Irinotecan is in the Topoisomerase Inhibitor class.

What is the chemical formula of Irinotecan?

Irinotecan has the molecular formula C33H38N4O6 and a molecular weight of 586.69 g/mol.

Sources

• DrugCentral drug card 1482 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200512 — compound record and bioactivity
• PubChem CID 60838 — chemical identifiers
• DrugBank DB00762 — drug record
• FDA UNII 7673326042 — substance identity
• DailyMed: FDA labels for Irinotecan — current prescribing information (label search)
• UniProt P22303 (ACHE) — target protein
• UniProt P08173 (CHRM4) — target protein
• UniProt P18825 (ADRA2C) — target protein
• UniProt Q96FL8 (SLC47A1) — target protein
• UniProt O15244 (SLC22A2) — target protein
• UniProt P03956 (MMP1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.